Ependymomas, neuronal and mixed neuronal–glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas

Newton, Herbert B.; Rudà, Roberta; Soffietti, Riccardo

doi:10.1016/b978-0-444-53502-3.00008-2

Cited by 3 publications

(2 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along with the loss of the Purkinje cell layer, there is also thinning of the medullary white matter [10] . On T2-weighted images, the lesion shows a pattern alternating between high and low signals with a distinctive striated appearance resembling ``tiger stripes,'' while on T1-weighted images, it often exhibits a hypointense signal [11] or isointense signal [12] . Although tiger stripe appearance is highly specific, it has been observed in other lesions [13] .…”

Section: Discussionmentioning

confidence: 99%

Lhermitte-Duclos disease in a 51-year old patient

Abdelrahman,

Abass,

Abdalla

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lhermitte-Duclos disease in a 51-year old patient

Abdelrahman,

Abass,

Abdalla

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

“…Given the rarity of PXA, this is a di cult limitation to overcome, yet our series is still one of the largest reported in the literature. Next, perhaps as a tertiary care center, we had a higher proportion of grade 3 aPXA patients (60%) compared to the 25-30% reported in the wider population [37]. While this may limit the generalizability of our series, it provides important outcomes data on the more aggressive variants of aPXA.…”

Section: Limitationsmentioning

confidence: 94%

Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience

Sullivan¹,

Chandler

Lesniak

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Report our institutional experience with pleomorphic xanthoastrocytoma (PXA) to contribute to limited data on optimal management. Methods Patients with pathologically confirmed PXA treated at our institution between 1990 and 2019 were identified. Demographic information, tumor grade, treatment variables, and clinical outcomes were collected from patient charts. Kaplan-Meier estimates were used to summarize two primary outcome measurements: progression-free survival (PFS) and overall survival (OS). Outcomes were stratified by tumor grade and extent of resection. Cox regression and log-rank testing were performed. Results We identified 17 patients with pathologically confirmed PXA. Two patients were excluded due to incomplete treatment information or < 6m of follow-up; 15 patients were analyzed (median follow-up 4.4y). Six patients had grade 2 PXA and 9 had grade 3 anaplastic PXA. The 2-year and 5-year PFS for the cohort was 57% and 33%, respectively; 2-year and 5-year OS was 93% and 75%, respectively. Patients with grade 2 tumors exhibited superior PFS compared to those with grade 3 tumors (2-year PFS: 100% vs. 28%, 5-year PFS: 60% vs. 14%), hazard ratio, 5.09 (95% CI:1.06–24.50), p = 0.02. Undergoing a GTR also yielded improved outcomes (hazard ratio: 0.38, p = 0.15). All but one (89%) of the grade 3 patients underwent RT. Conclusion The poor survival of the cohort, especially with grade 3 tumors, suggests the need for more aggressive treatment, including maximal resection followed by intensive adjuvant therapy. Better prognostics of tumor recurrence are needed to guide the use of adjuvant therapy.

show abstract